NEW YORK — The US Food and Drug Administration last week granted separate Emergency Use Authorizations for PCR-based SARS-CoV-2 tests developed by BioFire Diagnostics and the University of Massachusetts Medical School.
The BioFire Respiratory Panel 2.1-EZ is a point-of-care test designed to detect and differentiate between nucleic acids from SARS-CoV-2 and 20 other viral and bacterial respiratory pathogens — including various influenza A subtypes, respiratory syncytial virus, and Bordetella pertussis — in nasopharyngeal swabs.